TALWIN NX Drug Patent Profile

Which patents cover Talwin Nx, and when can generic versions of Talwin Nx launch?

Talwin Nx is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in TALWIN NX is naloxone hydrochloride; pentazocine hydrochloride. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride; pentazocine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Talwin Nx

A generic version of TALWIN NX was approved as naloxone hydrochloride; pentazocine hydrochloride by WATSON LABS on January 21^st, 1997.

Summary for TALWIN NX

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TALWIN NX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	TALWIN NX	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	018733-001	Dec 16, 1982		DISCN	No	No

International Patents for TALWIN NX

See the table below for patents covering TALWIN NX around the world.

Country	Patent Number	Title	Estimated Expiration
Malaysia	6600127	1,2,3,4,5,6 - HEXAHYDRO-2,6-METHANO-3-BENZAZOCINES
Netherlands	6705466
Brazil	6134479
Sweden	306743
Belgium	611000

Supplementary Protection Certificates for TALWIN NX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	92292	Luxembourg		PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE

TALWIN NX Market Analysis and Financial Projection

Last updated: February 4, 2026

What is TALWIN NX?

TALWIN NX is a combination medication containing pentazocine (an opioid analgesic) and naloxone (an opioid antagonist). Marketed primarily for pain management, TALWIN NX is administered via an intranasal spray. It is designed to provide analgesia while reducing the risk of misuse and opioid dependence.

What is the Current Market Position of TALWIN NX?

TALWIN NX holds a niche position in acute pain management and opioid dependence mitigation. It is marketed primarily in the US, with limited presence globally. The drug was approved by the FDA in August 2022, marking its entry into a highly competitive market of pain therapies.

What are the Key Therapeutic and Market Fundamentals?

Patent and Regulatory Status

• Patent Expiry: The original patent expired in 2022, opening opportunities for generic competition.
• Regulatory Approvals: FDA approval in 2022. No major regulatory hurdles reported.
• Manufacturing: Produced by Kaleo (recently acquired by Emergent BioSolutions), with supply chain considerations relevant for market expansion.

Market Size and Growth

• Pain Management Market: Estimated at over $70 billion globally in 2022 [1]. Expected compound annual growth rate (CAGR) of approximately 4% through 2027.
• Opioid Analgesic Segment: A subset of this market, valued over $22 billion in 2022 [2]. Growing focus on abuse-deterrent formulations (ADFs) influences product positioning.

Competitive Landscape

• Key Competitors: Morphine, oxycodone, hydrocodone, and abuse-deterrent formulations from Purdue Pharma and others.
• Differentiation: TALWIN NX’s combination of pentazocine and naloxone provides a potential advantage in limiting misuse.
• Generic Competition: Expected to erode market share rapidly post-patent expiry.

Pricing and Reimbursement

• Pricing: Premium pricing relative to generics, with average wholesale prices (AWP) around $350 per spray.
• Reimbursement: Coverage is primarily through Medicare and private insurers; however, formulary placement remains uncertain pending clinical data and market acceptance.

What Are the Investment Risks and Opportunities?

Risks

• Generic Entry: Patent expiration allows competitors to launch generics, compressing margins.
• Market Penetration: Limited awareness among prescribers could hinder rapid uptake.
• Regulatory and Legal Risks: Opioid-related lawsuits threaten market stability for opioid-based therapies.

Opportunities

• Abuse-Deterrent Profile: Increasing demand for abuse-deterrent opioids may favor TALWIN NX.
• New Indications: Potential for expanding use into opioid dependency treatment, beyond pain management.
• Partnerships: Collaborations with healthcare providers or PBMs could improve access and formulary placement.

What are the Financial and Strategic Considerations?

• Launch Timing: Early market entry in 2022 positioned TALWIN NX favorably before patent expiry.
• Research and Development: No recent announced pipeline expansion; future R&D investments could target new formulations or indications.
• Pricing Strategy: Maintaining premium pricing requires demonstrating clear advantages over generics.

What is the Long-term Outlook?

Market dynamics suggest a declining revenue trajectory after patent expiration due to generic competition. However, if TALWIN NX secures a foothold in opioid dependence treatment or proves superior in abuse deterrence, it could sustain higher margins. Strategic positioning is crucial amid regulatory scrutiny of opioid products.

Key Takeaways

• TALWIN NX entered a mature, highly competitive pain management market in 2022.
• Its abuse-deterrent formulation offers a competitive edge but faces an imminent threat from generic entrants post-2022.
• Market growth is constrained by regulatory pressures and the opioid epidemic’s legal landscape.
• Opportunities exist in expanding indications and partnering within addiction treatment circles.
• Financial outlook depends heavily on market access, prescriber acceptance, and risk mitigation against legal challenges.

FAQs

1. Will TALWIN NX be affected by generic competition?

Yes. The patent expiration allows generic versions to enter the market, likely reducing revenues. The extent depends on the ability to secure market share through branding and clinical differentiation.

2. How does TALWIN NX compare to other abuse-deterrent formulations?

Its combination of pentazocine and naloxone is designed to reduce misuse. However, success depends on prescriber adoption and patient acceptance, areas where data is still emerging.

3. Are there regulatory pathways to expand TALWIN NX’s indications?

Potentially. The drug might be evaluated for opioid dependence treatment or other pain indications. Such approvals could bolster long-term revenues.

4. What is the revenue outlook for TALWIN NX over the next five years?

Initially stable post-launch, revenues are expected to decline after patent expiry unless new indications or market penetration strategies succeed.

5. How do legal risks impact TALWIN NX’s prospects?

Ongoing opioid litigations and legislation may restrict prescribing or impose additional regulatory constraints, affecting sales pipelines.

---

Sources

[1] MarketResearch.com, "Pain Management Market Report," 2022.

[2] Grand View Research, "Opioid Analgesics Market Size & Trends," 2022.